Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Total Current Liabilities: 2020-2025

Historic Total Current Liabilities for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Sep 2025 value amounting to $7.7 million.

  • Insight Molecular Diagnostics' Total Current Liabilities fell 15.73% to $7.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.7 million, marking a year-over-year decrease of 15.73%. This contributed to the annual value of $7.3 million for FY2024, which is 1.13% up from last year.
  • Latest data reveals that Insight Molecular Diagnostics reported Total Current Liabilities of $7.7 million as of Q3 2025, which was up 15.15% from $6.7 million recorded in Q2 2025.
  • In the past 5 years, Insight Molecular Diagnostics' Total Current Liabilities ranged from a high of $19.8 million in Q2 2021 and a low of $6.7 million during Q2 2025.
  • Its 3-year average for Total Current Liabilities is $7.9 million, with a median of $7.7 million in 2023.
  • Its Total Current Liabilities has fluctuated over the past 5 years, first surged by 189.02% in 2021, then crashed by 40.57% in 2023.
  • Quarterly analysis of 5 years shows Insight Molecular Diagnostics' Total Current Liabilities stood at $14.1 million in 2021, then declined by 14.26% to $12.1 million in 2022, then plummeted by 40.57% to $7.2 million in 2023, then rose by 1.13% to $7.3 million in 2024, then declined by 15.73% to $7.7 million in 2025.
  • Its Total Current Liabilities stands at $7.7 million for Q3 2025, versus $6.7 million for Q2 2025 and $9.7 million for Q1 2025.